2017 News Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle  
07/24/17Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, July 27, 2017 at 2:00 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2017. The call can be accessed by dialing (844) 269-7720 (U.S. and Canada) or (574) 990-1148 (international), and entering passcode 51914278. To access the live audio webcast, or the subsequent a... 
Printer Friendly VersionDownload PDF
07/18/17Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies
SOUTH SAN FRANCISCO, Calif., July 18, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patient has been dosed at the Dana-Farber Institute in the Phase 1b/2 dose-escalation and cohort-expansion study of its reversible, non-covalent Bruton’s Tyrosine Kinase (BTK)-inhibitor, SNS-062, in adults with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia, Waldenstrom’s macroglobulinemia and mantle cell lymphoma that have progressed after p... 
Printer Friendly VersionDownload PDF
06/26/17Sunesis Pharmaceuticals Added to Russell Microcap® Index
SOUTH SAN FRANCISCO, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it was added to the Russell Microcap® Index when the Russell Investment Group reconstituted its family of U.S. indexes effective today, June 26, 2017. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes p... 
Printer Friendly VersionDownload PDF
06/23/17Sunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting
Vosaroxin Combination Demonstrates Encouraging Response Rates SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from a Washington University-sponsored Phase 1/Cohort Expansion trial of vosaroxin plus azacitidine in patients with myelodysplastic syndrome (MDS). The results are being presented today from 5:15 to 6:45 P.M. Central European Time in a poster session titled “Myelodysplastic ... 
Printer Friendly VersionDownload PDF
05/08/17Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
Sunesis to Host Conference Call Today at 2:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2017. Loss from operations for the three months ended March 31, 2017 was $9.4 million. As of March 31, 2017, cash, cash equivalents and marketable securities totaled $35.2 million. “Following recent regulatory developments, our reversible non-covalent BTK... 
Printer Friendly VersionDownload PDF
05/01/17Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML
Company’s Primary Development Focus is Non-Covalent Reversible BTK-Inhibitor SNS-062 Sunesis to Host Conference Call and Webcast in Conjunction with First Quarter 2017 Financial Results on Monday, May 8th at 11:00 AM ET SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) announced today that the Company will withdraw its European Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed/refractory acute myeloid... 
Printer Friendly VersionDownload PDF
04/03/17Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from an Ohio State University-sponsored preclinical study evaluating the efficacy of non-covalent BTK inhibitor SNS-062 in chronic lymphocytic leukemia (CLL) proprietary cell lines and patient samples. The study demonstrated that, unlike ibrutinib, SNS-062 inhibition of BTK signaling is unaffected by the presence of the C481S mutation and may address acquired resi... 
Printer Friendly VersionDownload PDF
03/28/17Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President Corporate Development and Finance and Chief Financial Officer of Sunesis, will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 8:40 AM Eastern Time at The Westin Grand Central in New York City. A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.... 
Printer Friendly VersionDownload PDF
03/22/17Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin
SOUTH SAN FRANCISCO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has submitted its responses to the European Medicine Agency (EMA) Day 180 List of Outstanding Issues issued by the Committee for Medicinal Products for Human Use (CHMP) as part of the centralized review process of the Marketing Authorization (MAA) for vosaroxin as a treatment for relapsed/refractory acute myeloid leukemia (AML) in patients aged 60 years and older.... 
Printer Friendly VersionDownload PDF
03/09/17Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2016. Loss from operations for the three months and year ended December 31, 2016 was $8.1 million and $36.5 million, respectively. As of December 31, 2016, cash, cash equivalents and marketable securities totaled $42.6 million. “We are mak... 
Printer Friendly VersionDownload PDF
03/02/17Sunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 9, 2017 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2016. The call can be accessed by dialing (844) 269-7720 (U.S. and Canada) or (574) 990-1148 (international), and entering passcode 59899543. To access the live audio webcast, or... 
Printer Friendly VersionDownload PDF
03/01/17Sunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8th at 10:40 AM Eastern Time at the Marriott Copley Place in Boston. A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Cal... 
Printer Friendly VersionDownload PDF
02/06/17Sunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13th at 5:30 PM Eastern Time at the Waldorf Astoria Hotel in New York.  A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of ... 
Printer Friendly VersionDownload PDF
01/23/17Sunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs
FDA Review of Investigational New Drug Application for SNS-062 Complete; Phase 1B/2 Study in Patients with Advanced B-Cell Malignancies to Begin Dosing in the First Half of 2017 Vosaroxin Day 180 List of Outstanding Issues Received; Company to go Before Scientific Advisory Group in April Prior to CHMP Opinion SOUTH SAN FRANCISCO, Calif., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced clinical and regulatory updates to its two lead programs, SN... 
Printer Friendly VersionDownload PDF